Olivier J, et al. - Authors evaluated whether or not an approach of performing repeat biopsies only if PSA kinetics are abnormal would be safe and sufficient to detect progression. The participants were divided into group 1 patients who had per-protocol 12-month repeat systematic biopsies (SB); group 2 patients did not. Between the 2 groups, no significant difference for progression and AS discontinuation rate was seen. Seemingly the PSA kinetic was accurate as a marker of tumour progression. The conduct of a multi-centre prospective trial to confirm these findings was supported in the results.